On the HCPLive Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.
September 11th 2024
The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.
Guselkumab/Golimumab Induction Safe and Effective for Ulcerative Colitis
Patients with ulcerative colitis treated with combination induction therapy with guselkumab plus golimumab followed by guselkumab monotherapy achieved higher rates of the several end points at week 38 as compared to either guselkumab or golimumab alone.
High-Dose Maintenance Upadacitinib Lengthens UC Remissions
A 30 mg dose of upadacitinib led to a 1 month longer clinical remission and approximately 20% of patients had less severe disease at 52 weeks, when compared with a 15 mg dose for patients with active ulcerative colitis.
Machine Learning Model Predicts Inpatient Mortality for IBD Patients
Risk factors associated with inpatient mortality, included increasing age, ulcerative colitis, IBD-related surgery, pneumonia, chronic lung disease, acute kidney injury, malnutrition, frailty, heart failure, blood transfusion, sepsis/septic shock, and thromboembolism.
Introducing The Qazi Corner: A Gastroenterology Newsletter Featuring Taha Qazi, MD
The Qazi Corner will be a quarterly newsletter led by Taha Qazi, MD, of the Cleveland Clinic and featuring new data, conference highlights, and perspectives of leading gastroenterologists.
Recommendations Call for COVID-19 Vaccinations for IBD Patients
There were 248 patients included in the study with genetic data, with no differences found in mean titer after 2 or 3 doses between carriers and non-carriers of HLA-A24 associated with severe disease during COVID-19 infections.